Edinburgh Research Explorer

Peptides for cell-selective drug delivery

Research output: Contribution to journalLiterature review

Original languageEnglish
Pages (from-to)186-192
Number of pages7
JournalTrends in Pharmacological Sciences (TIPS)
Volume33
Issue number4
Early online date15 Mar 2012
DOIs
Publication statusPublished - Apr 2012

Abstract

The ability to target specific cell types to achieve optimal distribution of therapeutic entities into diseased tissues, while limiting possible adverse off-target effects, has long been a goal of many research groups and pharmaceutical organizations. This review focuses on peptidic tissue-specific biomarkers that allow peptides to act as homing devices for specific tissue types or organs, with a focus on homing peptides (HPs) and cell-penetrating homing peptides (CPHPs). These HPs, in addition to promoting cellular uptake, can deliver a variety of cargos (drugs, oligonucleotides and nanoparticles) into cells. Two such peptides that have entered clinical trials are the tumor-homing peptide asparagine-glycine-arginine (NGR) (fused to human tumor necrosis factor), which selectively binds CD13, an aminopeptidase that is overexpressed on tumor blood vessels, and cyclo[Arg-Gly-Asp-D-Phe-(NMeVal)] (cRGD, cilengitide), an anti-angiogenic agent that targets the alpha(v)beta(3) and alpha(v)beta(5) integrins.

    Research areas

  • HUMAN IMMUNODEFICIENCY VIRUS, ADVANCED SOLID TUMORS, VIVO PHAGE DISPLAY, IN-VIVO, PENETRATING PEPTIDE, PHASE-II, ENDOTHELIAL-CELLS, HOMING PEPTIDE, PHENOTYPIC HETEROGENEITY, GLIOBLASTOMA-MULTIFORME

ID: 17424582